Company Profile

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells.  The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as graft-vs-host disease (GvHD) and NASH.

Latest Presentation

Industry Classifications

Sector:
Healthcare

Industry:
Biotechnology

NAICS:
Pharmaceutical Preparation Manufacturing (325412)

SIC:
Pharmaceutical Preparations (2834)

Contact Information

Investor Relations
Marek Ciszewski, J.D.
T: 630-707-8585
mciszewski@cytodyn.com

Company Contact
CytoDyn Inc.
1111 Main Street
Suite 660
Vancouver, WA 98660
T: 360-980-8524
F: 360-980-8549
info@cytodyn.com